Zika Virus Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Denmark, China, Canada, India - Size and Forecast 2024-2028

Zika Virus Therapeutics Market Size 2024-2028 

The zika virus therapeutics market share is expected to increase to USD 4.17 billion from 2023 to 2028, and the market’s growth momentum will accelerate at a CAGR of 4.5%. In the realm of infectious diseases, Zika virus infection holds significant importance due to its high incidence rate and the disease burden it imposes. This mosquito-borne illness can lead to a range of complications, including neurological disorders and congenital abnormalities. To facilitate the qualitative diagnosis of Zika virus infection, we offer a serology kit. This essential tool enables healthcare professionals to accurately detect the presence of Zika virus antibodies in patient samples. By employing this kit, we aim to support early and effective intervention, ultimately reducing the disease burden and associated comorbidities. Our commitment to providing reliable diagnostic solutions underscores our dedication to public health and disease control.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

The market is currently experiencing significant growth due to the pressing need for effective treatments against this infectious disease. Zika virus infection, primarily transmitted by Aedes mosquitoes, can lead to severe birth defects such as microcephaly in fetuses. The drug market is responding with potential treatments, including small molecule inhibitors. Sexual contact is also a known mode of transmission, adding to the urgency for developing therapeutics. Zika virus infections can manifest in various clinical symptoms, including rash, malaise, headache, low-grade fever, and arthralgia. Major players in the therapeutics industry, such as Roche, TIB Molbiol Group, DiaSorin, and Quest Diagnostics, are actively involved in research and development of Zika virus treatments. The market is expanding to address other mosquito-borne diseases like Dengue, Malaria, Typhoid, and Pneumonia, as they share similar transmission routes and clinical manifestations. Acetaminophen, a common over-the-counter medication for symptomatic relief, is not a treatment for Zika virus infection. The epidemic nature of Zika virus outbreaks necessitates the continued development and availability of effective therapeutics. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Market Driver

One of the key factors driving the global industry growth is the availability of serology kits for qualitative diagnosis of zika virus infection. The market has recently witnessed the approval of a serology kit, namely ZIKV Detect 2.0 IgM Capture ELISA, by InBios International Inc. for the qualitative diagnosis of zika virus immunoglobulin M (IgM) antibodies in the human serum. For instance, ZIKV Detect 2.0 IgM Capture ELISA is widely used for Zika diagnostic tests, it is marketed in the US.

Moreover, it is designed to identify the presence of IgM antibodies, which are produced by the body's natural immune system upon exposure to the zika virus. In addition, results obtained from ZIKV Detect 2.0 IgM Capture ELISA are used in conjunction with clinical observations, patient history, and other laboratory outcomes to ease the decision-making associated with patient management. Thus, the approval of ZIKV Detect 2.0 IgM Capture ELISA will boost the demand during the forecast period.

Significant Market Trend

Increasing efforts by government and private organizations to facilitate vaccine development is one of the key market trends that is expected to impact the industry positively in the forecast period. Along with the WHO and UNICEF, various other government and non-government bodies are taking various initiatives to develop a vaccine against the Zika virus. Some of the recent developments that are anticipated to propel the growth of the global market in the coming years are as follows:

• The NIAID is currently engaged in conducting a Phase I trial for a ZPIV. The vaccine is being tested in adults in a Flavivirus endemic area. The NIAID and the WRAIR are collaboratively conducting a Phase I trial for ZPIV accelerated vaccination schedule study.
• Private organizations, such as Bharat Biotech Ltd. and Takeda, are also developing purified, inactivated, whole virus vaccines (PIVs) against Zika virus infection.
• On May 4, 2022, Moderna announced its confirmation of an ongoing Phase 2 clinical trial of its mRNA-1893 candidate in the US and Puerto Rico.

Moreover, along with the WHO and UNICEF, various other government and non-government bodies are taking various initiatives to develop a vaccine against the Zika virus. Hence, such factors will boost the demand during the forecast period.

Major Market Challenge

One of the key challenges to the global zika virus therapeutics industry growth is the asymptomatic nature of the infection. A large infected patient population with Zika virus disease is estimated to be asymptomatic in nature and accounts for approximately 80%. This leads to the underdiagnosis of patients, leading to a decreased incidence rate of the infection globally.

Moreover, the asymptomatic nature of Zika virus infection not only influences the disease dynamics but also complicates the criteria of various studies that aim to quantify the asymptomatic transmission of the infection. Pregnant women in places where a Zika virus outbreak happens are generally monitored by a surveillance system, namely the RT-PCR and/or serology test. A study estimated that 19% of Zika virus-infected women were not diagnosed with the infection using this system, which accounted for approximately 7,000 consultations for Zika virus infection by the end of the study. Such factors may limit market growth in the coming years. Hence, such factors are hindering the market during the forecast period.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Johnson and Johnson - The company offers zika virus therapeutics such as acetaminophen injection under the brand name Ofirmev, for analgesic and antipyretic use.

The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Aurobindo Pharma Ltd.
• Bharat Biotech Ltd.
• BioVaxys Technology Corp.
• Emergent BioSolutions Inc.
• GeoVax Labs Inc.
• Granules India Ltd.
• Inovio Pharmaceuticals Inc.
• Merck and Co. Inc.
• Moderna Inc.
• Perrigo Co. Plc
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Valneva SE

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

By Product 

The acetaminophen segment is estimated to witness significant growth during the forecast period. The market is segmented based on various parameters, including the route of administration, therapeutic categories, and end-users. The market encompasses oral and injection-based antiviral medications, which are primarily aimed at medical intervention for severe cases. These medications offer symptomatic relief and supportive care for patients, while diagnostic testing and follow-up care are crucial components of the therapeutic process.

Get a glance at the market share of various regions Download the PDF Sample

The acetaminophen segment was the largest segment and valued at USD 8.20 billion in 2018. Vaccines represent a significant market segment, as they offer a proactive approach to preventing Zika virus infections. The immune system plays a vital role in the efficacy of vaccines, and advances in technology, such as computational modeling and genomic analysis, are driving the development of more effective vaccines. Hospitals, clinics, and homecare settings are key end-users in the market. Hence, such factors are fuelling the growth of this segment during the forecast period.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

Asia is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The Zika virus infection continues to pose a significant threat, particularly due to its association with severe birth defects, including microcephaly. Transmission primarily occurs through the bite of Aedes mosquitoes, although sexual contact can also facilitate its spread. Potential treatments for Zika virus infection are currently under development in the drug market. One such candidate is Emricasan, a small molecule inhibitor, which exhibits antiviral activity against the virus in laboratory studies. This compound targets the host protein caspase-8, inhibiting viral replication by disrupting viral entry and host factors. However, the emergence of drug-resistant strains necessitates continued research and development. Hence, such factors are driving the market in Asia during the forecast period.

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Product Outlook
  • Acetaminophen
  • Other NSAIDs
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

You may also interested in below market reports:

• Americas Immunochemistry Market: Americas Immunochemistry Market by Product and Application - Forecast and Analysis
• Vaccines Market: Vaccines Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
• Vaccine Research Market: Vaccine Research Market by End-user, Age Group and Geography -

Market Analyst Overview

The market is rapidly evolving due to heightened public health concerns and the urgent need for effective treatment options. The virus, transmitted primarily by the Aedes mosquito, can cause severe complications such as Microcephalus, congenital glaucoma, and optic neuropathy in foetuses. Zika virus biology and its transmission dynamics are critical areas of study, with genomic analysis and computational modeling driving advances in identifying effective drug targets.

Research has focused on small molecule inhibitors like Emricasan, which targets host factors such as caspase-8 to inhibit viral replication. Laboratory studies have shown promising antiviral activity against related viruses, but the drug development process faces challenges including patient recruitment difficulties, optimal dosing regimens, and ensuring a safety profile suitable for clinical trials. Market segmentation includes antiviral medications for Oral administration, targeting gastrointestinal tract absorption, and varied treatment modalities across Hospital, Homecare, and Clinic settings. Severe cases often necessitate medical intervention and supportive care, with diagnostic testing like the RT-PCR test kit from Siemens Healthcare GmbH and Mylab being crucial for Zika Virus Testing. Ethical considerations and endpoint selection are pivotal in human trials, with a focus on patient safety and approval and commercialization timelines. Repurposing existing drugs and exploring novel drug targets are strategies employed to combat drug-resistant strains and achieve broader efficacy. Advances in Nature Biomedical Engineering highlight the therapeutic potential, despite delays in drug availability and gaps in understanding the pathogenesis of Zika. The market is driven by commercial opportunities, influenced by reimbursement policies and the demand for innovative therapeutic approaches. Ongoing research and development efforts aim to address the neurological complications associated with Zika and enhance treatment strategies for affected individuals, ensuring better health outcomes and mitigating the impact of this virus.

Download PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2023 and 2028
• Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
• Accurate predictions about upcoming market growth and trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies